Vafai A
Department of Biomedical Sciences, University Of Illinois College of Medicine, Rockford 61107-1897, USA.
Vaccine. 1995 Oct;13(14):1336-8. doi: 10.1016/0264-410x(94)00073-v.
A varicella-zoster virus (VZV) seropositive individual was immunized with 100 micrograms of purified VZV TgpI-511 glycoprotein subunit antigen formulated with monophosphoryl lipid A. Serum samples were obtained during a 40-day period post-immunization (PI) and analysed by immunoprecipitation and virus neutralization tests. The results from immunoprecipitation studies revealed an increase in VZV anti-gpI antibody titer as early as 6 days PI which continued to rise during 40 days PI. In addition, virus neutralization tests showed a 21.0% VZV neutralization 6 days PI with an increase to a 96.7% VZV neutralization 40 days PI. These results suggested that the candidate VZV glycoprotein subunit vaccine (TgpI-511) was capable of boosting the production of neutralizing antibodies in the immunized VZV seropositive human subject.
一名水痘-带状疱疹病毒（VZV）血清反应阳性个体用100微克与单磷酰脂质A配制的纯化VZV TgpI-511糖蛋白亚单位抗原进行免疫接种。在免疫接种后（PI）的40天内采集血清样本，并通过免疫沉淀和病毒中和试验进行分析。免疫沉淀研究结果显示，早在免疫接种后6天VZV抗gpI抗体滴度就有所增加，并在免疫接种后的40天内持续上升。此外，病毒中和试验显示，免疫接种后6天VZV中和率为21.0%，免疫接种后40天增加到96.7%。这些结果表明，候选VZV糖蛋白亚单位疫苗（TgpI-511）能够在免疫的VZV血清反应阳性人体受试者中促进中和抗体的产生。
